Lewy Body Dementias

Neurophysiological biomarkers for Lewy body dementias

OBJECTIVE Lewy body dementias (LBD) include both dementia with Lewy bodies (DLB) and Parkinson's disease with dementia (PDD), and the differentiation of LBD from other neurodegenerative dementias can be difficult. Currently, there are few biomarkers which might assist early diagnosis, map onto LBD symptom severity, and provide metrics of treatment response. Traditionally, biomarkers in LBD have...

Caregiver Burden in Lewy Body Dementias

Magnetic resonance imaging in lewy body dementias.

Dementia with Lewy bodies (DLB) and Parkinson's disease dementia (PDD) share common clinical, neuropsychological and pathological features. In clinical diagnosis, distinguishing between these conditions and other dementia subtypes such as Alzheimer's disease (AD) can be difficult. Despite the development of consensus diagnostic criteria, sensitivity for diagnosis remains low, especially outside...

Disease-modifying therapeutic directions for Lewy-Body dementias

Dementia with Lewy bodies (DLB) is the second leading cause of dementia following Alzheimer's disease (AD) and accounts for up to 25% of all dementia. DLB is distinct from AD in that it involves extensive neuropsychiatric symptoms as well as motor symptoms, leads to enormous societal costs in terms of direct medical care and is associated with high financial and caregiver costs. Although, there...

Peripheral inflammation in prodromal Alzheimer’s and Lewy body dementias

OBJECTIVES There is growing evidence for the role of systemic inflammation in Alzheimer's disease (AD) and other neurodegenerative diseases; however the systemic inflammatory profile in dementia with Lewy bodies (DLB) has never before been investigated. This study aimed to characterise systemic inflammatory mediators in established DLB and AD, as well as in their prodromal, mild cognitive impai...